BioCardia, Inc. (BCDA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.4100

+0.0300

(+2.17%)

As of 10:24AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	1.3800
Open	1.4200
Bid	1.3700 x 1200
Ask	1.4200 x 1300
Day's Range	1.3550 - 1.4200
52 Week Range	1.1000 - 5.1000
Volume	5,537
Avg. Volume	758,100

Market Cap	24.599M
Beta (5Y Monthly)	1.33
PE Ratio (TTM)	N/A
EPS (TTM)	-0.7460
Earnings Date	Aug 10, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	9.10

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCDA

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

BioCardia, Inc.
Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
28 days agoArgus Research

All

News

Press Releases

Research Reports

Zacks
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call today at 4:30 PM ET. Following management’s formal rem
- EuroDry Ltd. Sets Date for the Release of First Quarter 2022 Results, Conference Call and Webcast
  GlobeNewswire
- FONAR Announces 3rd Quarter and Nine-Month Period Financial Results for Fiscal 2022
  Newsfile
InvestorPlace
Follow the Insiders and Buy the Dip in These 3 Stocks
This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here. A Recession Is Now “Inevitable” On Thursday, the Commerce Department reported that U.S. GDP had shrunk 1.4% from the prior year. “There are two realistic scenarios for how the coming months play out. Both end with recession,” noted Lisa Beilfuss of the Barron’s Advisor editorial team. “Either the Fed sufficiently fights inflat